CROI 2007: Index of Coverage

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

Key Links:

By Topic:

Search:

Antiretrovirals in Development

An Alternative NNRTI, TMC278, Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Another Integrase Inhibitor -- Elvitegravir (GS-9137) -- Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
79% of Treatment-Experienced Patients on MK-0518 Plus OBT Achieve Viral Load of Less Than 400 Copies at Week 16 (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Phase 3 Results of Two Key Trials of Maraviroc, the First-in-Class CCR5 Antagonist (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

HIV/HAART Complications

Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Incidence of Non-AIDS-Defining Malignancies in Persons With HIV (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Immune Suppression While on Antiretroviral Therapy Predicts Risk of Non-Opportunistic Diseases (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

HIV Drug Resistance

Emergence of Drug Resistance and First-Line Combination Therapy in the Swiss HIV Cohort Study (February 26, 2007)
To view original study poster, click here (PDF).
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
More Than 10% of U.S. Patients in 11 U.S. States With Either Newly or Recently Acquired HIV May Harbor Resistant Virus (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

HIV Prevention

Benefits of Breast-Feeding Might Outweigh Risk of Vertical HIV Transmission in Developing Countries, Studies Say (February 27, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

Salvage Therapy

A Research Update on Tipranavir (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

Treatment Strategies

Coverage of the 14th Conference on Retroviruses and Opportunistic Infections (CROI) (April 2007)
To read PDF, click here
In Infectious Diseases in Corrections Report, from Infectious Diseases in Corrections Report
New Developments in the Management of HIV Treatment-Naive Patients (February 28, 2007)
Includes an analysis of research examining once-daily regimens, the use of viral decay rate to assess treatment efficacy, and issues related to primary HIV drug resistance.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Predictors of Virologic Rebound on Lopinavir/Ritonavir Monotherapy (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
TILT: A Look at the Role of Interleukin-2 in Treatment Interruption Leans Toward the Negative (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Racial Disparities in HIV Diagnosis, Access to Care and Treatment Effects (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Interleukin-2 Expands Select CD4+ T-Cell Populations, but Has No Effect on HIV-Specific Immune Responses (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

Virology and Immunology

Molecular Snapshots From CROI 2007: Highlights in Virology and Immunology, From HIV Variation and Endogenous Retroviruses T-Cell Memory and Exhaustion (January/February 2007)
By Richard Jefferys.
In IAVI Report, from International AIDS Vaccine Initiative

Pre-Conference News

14th Conference on Retroviruses and Opportunistic Infections: Official Web Site (Regularly Updated)

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.